Literature DB >> 19479120

Measuring the prevalence of chronic itch in the general population: development and validation of a questionnaire for use in large-scale studies.

Uwe Matterne1, Tamara Strassner, Christian J Apfelbacher, Thomas L Diepgen, Elke Weisshaar.   

Abstract

Itching is the most frequent symptom in dermatology. Little is known about its occurrence and its characteristics in the general population. Instruments specifically designed to measure itch are scarce. The aim of this pilot study was to develop and validate an instrument measuring prevalence and characteristics of chronic itch in the general population. A questionnaire was developed and administered to a sample from the general population (n = 200) and a sample (n = 100) of itch-clinic patients. Life time prevalence of itch was 22.6% in non-patients and 100% in patients. Principal component, internal consist ency and correlational analyses revealed the instrument to be able to reliably and validly measure itch. Strength of itch was higher in patients and was associated with itch- related quality of life and affect in both groups. Preliminary results indicate that itch is prevalent in the general population. We intend to utilize this parsimonious and easy-to-administer questionnaire in a forthcoming population-based study.

Entities:  

Mesh:

Year:  2009        PMID: 19479120     DOI: 10.2340/00015555-0641

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  19 in total

Review 1.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?

Authors:  Nicholas K Mollanazar; Peter K Smith; Gil Yosipovitch
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 2.  [Health services research in dermatology. Current status].

Authors:  N Franzke; M Augustin
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

3.  Chronic pruritus: clinics and treatment.

Authors:  Sonja Grundmann; Sonja Ständer
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

4.  Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch.

Authors:  Jialie Luo; Jing Feng; Guang Yu; Pu Yang; Madison R Mack; Junhui Du; Weihua Yu; Aihua Qian; Yujin Zhang; Shenbin Liu; Shijin Yin; Amy Xu; Jizhong Cheng; Qingyun Liu; Roger G O'Neil; Yang Xia; Liang Ma; Susan M Carlton; Brian S Kim; Kenneth Renner; Qin Liu; Hongzhen Hu
Journal:  J Allergy Clin Immunol       Date:  2017-08-11       Impact factor: 10.793

Review 5.  Role of macrophage TRPV4 in inflammation.

Authors:  Bidisha Dutta; Rakesh K Arya; Rishov Goswami; Mazen O Alharbi; Shweta Sharma; Shaik O Rahaman
Journal:  Lab Invest       Date:  2019-10-23       Impact factor: 5.662

6.  Five-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices.

Authors:  Nicole Fett; Kevin Haynes; Kathleen Joy Propert; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2014-01-28       Impact factor: 11.527

Review 7.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

8.  Efficacy and onset of action of hydrocortisone acetate 2.5% and pramoxine hydrochloride 1% lotion for the management of pruritus: results of a pilot study.

Authors:  Leon H Kircik
Journal:  J Clin Aesthet Dermatol       Date:  2011-02

9.  Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.

Authors:  Sonja Ständer; Dorothee Siepmann; Ilka Herrgott; Cord Sunderkötter; Thomas A Luger
Journal:  PLoS One       Date:  2010-06-04       Impact factor: 3.240

10.  Itch as a patient-reported symptom in ambulatory care visits in the United States.

Authors:  Melissa Shive; Eleni Linos; Timothy Berger; Mackenzie Wehner; Mary-Margaret Chren
Journal:  J Am Acad Dermatol       Date:  2013-07-16       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.